Chronic obstructive pulmonary disease (COPD) affects 15-25 million Americans and over 300 million people around the world. The COPD Foundation is a global organization whose mission is to prevent and cure COPD and to improve the lives of all people affected by it. The year 2014 marks the 10th anniversary of the COPD Foundation. The Foundation works to accomplish its mission through a unique partnership between patients, patient families, health care providers, investigators, academic institutions, government agencies and industry. This partnership has led to real progress in awareness, advocacy, education, and research, but much more needs to be done. 
were unaware of existing COPD guidelines. Both patient and physician surveys demonstrated continued confusion about the diagnosis of COPD and treatment choices. In 2004, the National Institutes of Health (NIH) funding for COPD research stood at $66 million compared to $205 million for Parkinson's research, $716 million for breast cancer research, and $2.9 billion for AIDS research. [4] [5] It was in this setting that the COPD Foundation was launched. The primary goal of the Foundation was to push for a broader, better funded research agenda, but Foundation leadership soon realized that there were too many gaps in COPD care to concentrate on a research agenda alone. Over the last 10 years the Foundation has concentrated not only on the need for increased research, but also on increasing awareness/advocacy, education for patients, family members, and health care providers, providing patient assistance and a vehicle for the patient voice. The partnership between patients, patient families, health care providers, investigators, academic institutions, government agencies and industry has led to real progress but much more needs to be done. This manuscript will review some of the accomplishments of the Foundation in the 10 years of its existence ( Figure 1 ).
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Established with the financial and organizational assistance of sister organization, the Alpha-1 Foundation, the COPD Foundation was created by a unique collaboration of individuals with COPD and scientific and clinical leadership in direct response to the scarcity of resources, education and information about the disease that left many patients, families and caregivers with nowhere to turn for help. 6 The COPD Foundation is a global organization whose mission is to prevent and cure COPD and to improve the lives of all people affected by it. The COPD Foundation is currently in the process of incorporating as a nonprofit organization (Fundación EPOC) in Spain. This incorporation will allow the Foundation to organize a greater global COPD initiative and establish a broader platform for more global COPD community collaboration to reach common goals in the fight against COPD.
In 2014, the COPD Foundation was accredited by the National Health Council under its Standards of Excellence Certification Program for Voluntary Health Agencies. This is the highest quality measure that a health-related nonprofit organization can achieve. 
Patient/Family Education
The COPD Foundation's free educational materials, both printed and available for digital download (http:// www.copdfoundation.org/ Learn-More/EducationalMaterials/Downloads-Library.aspx), allow members of the COPD community to improve their disease selfmanagement, improve medication adherence, comply with health care team recommendations and improve their quality of life. 7 The Foundation ensures that educational materials are easy to understand, current, and accurate. The educational materials also provide awareness and education on Alpha-1, the genetic form of COPD, and encourage testing for those at risk. The Foundation's educational materials portfolio is extensive including:
• The 1s, 2s, and 3s of COPD This booklet contains current information on COPD and spans topics including COPD diagnosis and management, anxiety and depression, exacerbations, and a list of COPD resources.
• COPD Big Fat Reference Guide (BFRG®)
The BFRG is a comprehensive publication that features in-depth explanations of COPD, nutrition tips, exercise demonstrations, device utilization and a wealth of information for the individual with COPD, care giver and family.
• COPD Slim Skinny Reference Guides (SSRGs®)
The COPD Slim Skinny Reference Guides (SSRG) is a series of 10 chapters condensing specific information from the BFRG. The 10 chapters of the SSRG include issues related to COPD treatment and therapies, travel, exercise and oxygen therapy. In 2013, the Foundation added a new SSRG titled Hospitalizations and the Transition Back to Home.
• Also new in 2013 was the release of a Disaster Preparedness ToolKit (DPT) that was created as a direct result of the experiences and lessons learned from the devastation from Superstorm Sandy and Hurricane Katrina. This is an essential resource for individuals with COPD and health care providers on how best to prepare for disasters.
In the past year, the COPD Foundation has translated these educational materials into 9 languages including: Arabic, Chinese, French, German, Hindi, Italian, Japanese, Portuguese and Spanish. Plans are in the works for multiple other translations.
The COPD Digest was launched at the American Thoracic Society(ATS) Conference in 2004, as the first educational outreach initiative of the COPD Foundation.
For personal use only. Permission required for all other uses.
Published quarterly, the COPD Digest is the first free internationally distributed magazine on COPD and features COPD patient success stories and consumer savvy information, along with legislative updates, and Foundation program updates. The COPD Digest offers practical advice, news and information on treatment and resources to COPD patients, health care providers, families, and caregivers. As of 2014, there are 250,000 individuals receiving the COPD Digest in print and online.
In 2009, the COPD Foundation collaborated with WebMD to launch the Lung Health Check, a self-assessment offered on WebMD.com powered by WebMD's proprietary software and clinical algorithms. It is estimated that 87.5% of adults using the internet for health related topics have visited WebMD (within the last year), a website dedicated to delivering reliable health information to the public. 8 Every month the WebMD site receives approximately 64 million visitors and 2.4 million have been diagnosed with COPD. 8 The Lung Health Check survey includes a variety of lung health and COPD-related questions and provides the user with educational reports tailored to his or her needs based on the answers that he or she provides. To date, more than 600,000 people have participated in this survey, including over 177,000 reporting a COPD diagnosis and over 318,000 reporting no COPD diagnosis but concerned that they may have COPD. As part of the collaboration between WebMD and the COPD Foundation, blinded data from Lung Health Check respondents was released to the Foundation for analysis and, ultimately, presentation at scientific meetings and publication in peer-reviewed literature. The Information Line currently provides peer-to-peer support to those living with COPD and COPD caregivers in English, Spanish, French, and Italian as well as translation capabilities in over 175 languages. The Associates are required to continue training with a robust curriculum on relevant topics and information necessary to keep current and provide comprehensive resources to peers.
In fiscal year 2013, the Information Line handled over 85,000 individual contacts that included telephone, email and live chat through the website. The average contact volume now totals more than 5,000 a month -more than 150 individuals reached daily. In an effort to promote large scale awareness for COPD, in 2010, the COPD Foundation launched the COPD Shuttle: Journey to the Center of the Lung, a 20-seat, state-of-the-art mobile, motion simulator. The COPD Shuttle is designed to make viewers feel as if they are inside the body, offering an interactive rare glimpse into the lungs, which heightens their understanding of COPD, and provides a catalyst for thousands to seek assessment and treatment. Over 10,000 individuals have taken a Journey to the Center of the Lungs in the COPD Shuttle. (http://bit.ly/copdshuttle) 9 In 2009, the COPD Foundation began lobbying for COPD to be included on the Centers for Disease Control and Prevention's (CDC) Behavioral Risk Factor Surveillance System (BRFSS), the world's largest, on-going, telephone health survey. 10 The BRFSS is the primary data set used by health departments and public health organizations when prioritizing program activities and monetary resources as it details disease and behavioral issues down to the local level. The BRFSS data is reported by the states to the CDC which tracks national trends, identifies outliers, compares co-morbid conditions, and publishes results in the Mortality and Morbidity Weekly Report (MMWR) .
Awareness and Adovcacy
Despite the growing burden of COPD, the BRFSS had never included a core standard question regarding COPD prevalence. The space on each year's BRFSS is highly coveted. Recognizing the need to include a core question about COPD, the COPD Foundation embarked on a comprehensive grassroots campaign. The COPD Foundation strongly believes in the power of the patient voice to influence change. Patient representatives in each congressional district, in a program called Operation 435, combined advocacy with an educational campaign to influence decision makers for the BFRSS, usually state health department officials. A core COPD question was added in 2011 and NHLBI made the funds available to states to implement an optional module that explored health care utilization.
Data from the 2011 BRFSS was initially published in the CDC's MMWR. The report, Chronic Obstructive Pulmonary Disease Among Adults-United States, 2011, indicated that over 15 million Americans, 6.3% of adults, have been diagnosed with COPD. 11 The prevalence rate varied from a low of 3.9% in Washington and Minnesota to a high of 9.3% in Kentucky. 11 The report further highlighted the severity of the COPD epidemic, but also confirmed the changing face of the disease -more women, more middle-aged, more never smokers (25% of those with COPD). In addition, for the first time the report suggested that COPD was a health care disparity issue: those making less than $25,000 a year are much more likely to carry a COPD diagnosis.
In addition to the staggering number of individuals affected by COPD, the economic burden of COPD is extensive. The Bureau of Labor Statistics estimates that 2.8 million work days are lost each year due to unplanned absences. 12 This level of absenteeism cost American business more than $74 billion. According to the August 2012 report, The Disability of COPD, COPD accounts for approximately $43 billion in lost productivity from reduced work among individuals. 13 The statistics are significant. However, the report's conclusion is even more significant: COPD is treatable and the economic burden of COPD can be significantly reduced. The COPD Foundation has attempted to address this issue by creating a tool kit for businesses in hope of improving the health care of workers and thus addressing issues of absenteeism and presenteeism (Table 1) .
14 In 2012, the COPD Foundation received the Aesculapius Award of Excellence for health-related television public service announcements, for its DRIVE4COPD campaign, the largest national public awareness campaign designed to increase public awareness of COPD ever launched. The Aesculapius Award of Excellence, awarded by the Health Improvement Institute, is designed to promote and to encourage excellence in the communication of good information about healthy lifestyles, disease prevention, and health care treatments. In this same year, the COPD Foundation assumed responsibility for DRIVE4COPD as a campaign of the COPD Foundation. Since the campaign's inception in 2010, the Foundation partnered, with Boehringer-Ingelheim Pharmaceuticals Inc. and others on the DRIVE4COPD campaign. DRIVE4COPD has screened over 2.7 million individuals to date and has generated widespread awareness for COPD. DRIVE4COPD was named the "official health initiative of NASCAR®" and has extended awareness to NASCAR's® extensive fan base and the Fortune 500 companies that comprise the NASCAR® sponsors. NASCAR® was selected as a target audience for DRIVE4COPD because NASCAR® fans are among the largest demographic of at risk for COPD individuals in the country. In fact, individuals with COPD are 30% more likely to be a NASCAR® fan than an individual that does not have COPD. Figure 2 shows the states found to have the highest incidence of COPD and the location of the NASCAR® tracks. This overlap highlights the rationale to target NASCAR® fans through DRIVE4COPD.
Heath Care Provider Education
Health care provider education has been an ongoing focus for the Foundation. Seven years ago the Foundation, in partnership with the NewYork-Presbyterian Healthcare System, launched its COPD Pocket Consultant. Since that time the card has been updated multiple times and over 400,000 cards have been distributed to health care providers nationwide at no charge. The initial versions of the card were based upon the established Global Initiative for chronic Obstructive Lung Disease (GOLD) Guidelines with the permission of the GOLD leadership. 15 The version of the COPD Pocket Consultant that launched in 2013 is significantly different. The Foundation's scientific leadership recognized the large number of excellent existing COPD guidelines, including those from GOLD, the ATS /European Respiratory Society (ERS), and National Institute for Health and Clinical Excellence. [15] [16] [17] All of these provide a wealth of wellFor personal use only. Permission required for all other uses. The most recent version of the Pocket Consultant, a 6-panel, folded card, is based upon 7 severity domains: spirometry, symptoms, exacerbations, oxygenation requirements, the presence of emphysema, chronic bronchitis, and comorbidities. The Pocket Consultant Guide card is available in a 2-panel version that provides basic information on diagnosis and therapy and two, 6-panel versions that include information on diagnostic tools and commonly used medications, one with generic names and one with brand names. The card is meant to be a simplified guide, not a formal guideline. The COPD Foundation hopes that by addressing the severity domains a more comprehensive, patient-centered approach can be developed. 19 The Foundation has launched a free smart phone application (app) which allows the Pocket consultant to be used in an interactive format. The app can be downloaded from the i-Phone APP store by searching under COPD Foundation. The first version of the app listed the available generic medications, but subsequent versions will allow the user to toggle between brand and generic drug names, and a version with European medications listed is also being developed. An Android version is also being developed.
Finally, recognizing the importance of making these tools as effective as possible in clinical practice, the Foundation has launched a social collaboration website for the Pocket Guide (pocketconsultantguide.copdfoundation.org) which is designed to provide a forum for health care providers to comment and make suggestions so that subsequent versions can be more effective.
The Foundation has also released another free app allowing health care providers to teach appropriate inhaler techniques to patients. This app can be found at the APP store by searching under Use Inhaler.
In 2010 the COPD Foundation launched the Lung Health Professional (LHP), a magazine designed for health care providers including primary care physicians, nurses, and respiratory and physical therapists. With a circulation of over 30,000, LHP covers a wide range of pulmonary issues beyond COPD, including editions on interstitial lung disease, pulmonary vascular disease, mycobacterial diseases, influenza and lung cancer.
In 2011, the Journal of COPD became the official scientific journal of the COPD Foundation. In 2014, in response to the unmet request from the COPD scientific and physician community for an open access journal on COPD, the COPD Foundation launched its own open access journal titled Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF). Led by James Crapo, MD, Editor-in-Chief, and an editorial board comprised of world leaders in COPD from across the globe, the JCOPDF (journal.copdfoundation.org) provides the COPD community with an outlet for high-quality articles that can be accessed quickly and easily.
Figure 2. Correlation of BRFSS Data to NASCAR Track Location
Since 2009, the COPD Foundation has partnered with established continuing medical education (CME) providers including MedscapeCME, the leading provider of online CME,on 5 online CME activities. In addition to online CME, the Foundation has held multiple health care provider education days, including several cosponsored by 1199 Service Employees International Union (SEIU) United Healthcare Workers East, the nation's largest health care union. 20 In 2009, the COPD Foundation established an accredited COPD Education Program® designed for physicians, nurses, respiratory therapists and allied health professionals caring for individuals living with COPD. The Educator Course is an 8-hour course with 7 topics and a hands-on spirometry workshop. Upon completion of the course, individuals are certified by the COPD Foundation COPD Educator Program. In that same year, recognizing the importance of exercise and pulmonary rehabilitation, the COPD Foundation started the Pulmonary Education Program, which is geared towards supporting pulmonary rehabilitation clinics' efforts to promote long-term benefits of rehabilitation by connecting patients to resources after graduation.
In 2011, the COPD Foundation expanded CME education to include the COPDUSA conference series modeled after the very successful COPD conference series held in the United Kingdom every other year for the past 18 years. This European conference has been recognized as the premier COPD event bringing together investigators from around the world. COPD Foundation leadership, working with leaders of the European conference series, established the COPDUSA series alternating years with the more established European series. COPD7USA was held in Washington, DC, in December 2011, COPD8USA was held in Chicago in June 2013, and COPD9USA is scheduled for Chicago in June 2015. The COPDUSA series has expanded the program by integrating patients into the conference programming. The COPDUSA conference includes research, clinical, care delivery and patient tracks. Presentations from the conference and the online CME activity from COPD8USA are available at www.copdconferencesusa.org.
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Research
Comorbidities
The Foundation has been actively involved in numerous research projects. Recognizing the importance of comorbidities, in 2006 the Foundation surveyed some 3000 individuals with COPD. 22 Comorbidities were extremely common. Over 50% of those surveyed had 6-10 comorbid illnesses and over 20% had over 11 comorbidities. Although most of these patients were symptomatic from their COPD and many had been hospitalized for COPD, self-knowledge was low and COPD was undertreated compared with other conditions such as hypertension and hyperlipidemia which were generally asymptomatic. Since that time, numerous studies have stressed the importance of addressing comorbidities in COPD care. With concern over the underutilization of established guidelines in COPD, the Foundation evaluated potential barriers to adherence. 23 In response to an Agency for Healthcare Research and Quality statement questioning the usefulness of spirometry, the COPD Foundation cosponsored a workshop with the NHLBI in June 2008. Out of that conference a threestage approach was developed using a brief questionnaire, peak flow testing and diagnostic quality spirometry. Between June 2008 and December 2009 the COPD Foundation screened almost 6000 adults, mostly in health fairs around the country using the Mobile Spirometry Units.
A normal peak flow, viewed as equal to or over 70% predicted missed only 5% of people with significant COPD, FEV1<60% according to American College of Chest Physicians guidelines, 24 and missed less than 3% of those with severe obstruction, FEV1<50% predicted according to GOLD guidelines. 15 An abnormal peak flow, viewed as <70% predicted was associated with abnormal spirometry over 93% of the time. The abnormal spirometry could represent either obstructive or restrictive diseases, but certainly suggested that an abnormal peak flow required further evaluation including formal spirometry testing. The study suggested that the combination of a simple questionnaire and peak flow testing could better define those who needed to undergo spirometry to determine the presence of COPD. 25 A major gap in the study was that peak flow testing could miss a significant percentage of individuals with milder disease, including potentially those with frequent exacerbations who might benefit from more aggressive therapy. Following completion of that study, the NHLBI released a request for proposals (RFP) with the aim to develop a validated, simple questionnaire including exacerbation questions and link it to peak flow testing in hope of developing a better way to determine who needs spirometry. That multi-institutional study ( COPDGene® COPD Genetic Epidemiology (COPDGene®) is an NHLBI-funded, multi-institutional study of past and current smokers to identify the genetic factors that control the development and progression of COPD and to facilitate development of specific therapies for the different subtypes of COPD. 26 The first 5-year phase of the COPDGene® Project created a cohort of over 10,000 smokers who are at risk for or express one of the various stages of COPD (GOLD grades 1-4) . 15 This cohort was enrolled through 21 U.S. medical centers, and the participants were phenotyped using inspiratory and expiratory high-resolution computed tomography (HRCT). A genome-wide association study was done on the entire cohort and pilot whole exome sequencing was conducted. The overall hypothesis underlying COPDGene® is that extensive phenotypic and genetic data will enable creation of a new classification system for COPD, with distinct diagnostic, prognostic and therapeutic implications. COPDGene® has secured funding from the NIH for Phase 2 (2012-2017).
The Foundation has partnered with COPDGene® investigators since the onset of the study, including sponsoring the initial investigator meeting. The Foundation organized an Industry Advisory Committee (IAC) to involve scientific representation from industry and provide ancillary support to complete the genome wide association studies (GWAS) and HRCT chest scanning on the entire cohort, fund the longitudinal follow-up, purchase equipment, commission the telephony platform and provide other items not funded in the original NHLBI grant. This collaboration created a new model of public-private engagement that the Foundation continues to utilize to advance its mission. The COPD Foundation continues to support the goals in Phase 2 of COPDGene®, including longitudinal follow -up.
Spiromics
The SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) collects and analyzes multiple types of information, including blood tests and X-ray images of the lungs, from patients with COPD to identify subpopulations of COPD patients (groups of patients with similar symptoms, genes, physical signs of disease, etc.) and intermediate outcome measures. The study will also provide a better understanding of the natural course of COPD, and will allow scientists and clinicians to share data about COPD to improve other studies of the disease. SPIROMICS is funded by the NHLBI and is coordinated by the University of North Carolina at Chapel Hill. 27 The COPD Foundation is supportive of SPIROMICS and has been actively partnering with SPIROMICS investigators in study participant recruitment drives.
The COPD Foundation Biomarkers Consortium
Biomarkers are tests that can be used as end-points for clinical trials. There are different types of biomarkers, such as blood tests, breathing tests, radiologic (imaging of the lung) studies, exercise tests or quality of life measures. Despite the prevalence and impact of COPD, for years only a handful of biomarkers have been approved for use in clinical trials by the FDA: FEV1, mortality, and more recently COPD exacerbations. In 2010 the COPD Foundation was approached by the FDA and asked to hold a workshop bringing together academic clinical investigators and experts, government agencies, and the pharmaceutical industry, in hopes of addressing this research gap. The outcome of that workshop led the COPD Foundation to form the COPD Biomarkers Qualification Consortium (CBQC). This unique approach brought together interested parties from academia and industry to begin the process of sharing clinical trial data (and costs for data compilation and analysis). The CBQC has now submitted data to the FDA for one potential new biomarker -fibrinogen. In addition, the group is preparing summaries for 2 additional biomarkers -the St. George's Respiratory Questionnaire and the 6-minute walk test. 28 The goal is to add to the limited set of currently approved biomarkers, and stimulate additional studies. A second biomarkers workshop held in early 2013 opened conversation on the next group of potential biomarkers to submit for FDA evaluation. Plans are also underway to work with European regulators in a similar approach.
Bronchiectasis
Bronchiectasis is a common finding in COPD patients and many with bronchiectasis have COPD. 
COPD Hospitalizations and Rehospitalizations
The cost of care for COPD in this country now stands at over $50 billion dollars a year. 29 Over 70% of that cost reflects exacerbations and over 90% of that 70% reflects hospitalizations for exacerbations. 30 Hospital readmissions have been singled out for improvement by the CMS National Strategy for Quality Improvement in Health Care. As part of the Affordable Care Act, CMS is aiming for a 20% reduction in 30-day readmissions potentially preventing 1.6 million hospitalizations and saving an estimated $15 billion. Combining financial incentives and penalties, the Affordable Care Act seeks to promote coordination across the continuum of care. 31 The first 3 core rehospitalization measures -acute myocardial infarction, congestive heart failure and pneumonia--have been in place for several years. The 30-day, all cause readmission rate for those with an index admission of COPD has persistently been over 20%. 32 COPD will be added as the next core measure starting fiscal year 2015. In October 2013, in Washington, DC, the COPD Foundation convened a COPD Readmissions Summit: Integrating COPD into Patient-Centered Hospital Readmission Reduction Programs to bring experts together representing all the stakeholders of COPD, share best practices and develop a consensus on how best to address this issue moving forward. A workshop report is in development and the Foundation continues to make readmissions a priority. It is in the process of establishing a Readmission Collaboratory to capture and share best practices and continue the dialogue to improve health outcomes and reduce readmissions.
Patient-Centered Outcomes Research Institute
Recognizing that comorbidities are critical elements of COPD care and understanding the importance of patient-centered rather than disease-centered care, the Foundation has been a partner in a number of projects that the Patient-Centered Outcomes Research Institute (PCORI) has accepted for funding (Table 2 ). In 2014, the COPD Foundation was awarded a Patient-Powered Research Network (PPRN) grant from PCORI.
The Next Ten Years
The COPD Foundation remains committed to broadening a successful COPD research agenda--a research agenda aimed at defining and treating the different subtypes of COPD. All COPD is not the same, just as all cancer is not the same, and as with cancer therapy, COPD therapies need to be individualized. Two major hurdles slow research studies: cost and enrollment of appropriate study participants. In 2012, Forbes reported that the estimate for a major pharmaceutical company to develop a drug from discovery to market could cost at least $4 billion dollars. 37 An estimated 80% of total trials are delayed at least one month because of unfulfilled enrollment. 38 The COPD Foundation believes that a COPD Research Registry can help to reduce the burden of both cost and enrollment and ultimately provide a resource to speed clinical trials. Therefore, the COPD Foundation is committed to expanding the PPRN to develop the largest database of people with COPD and their medical information in the world. The technology platform to support this initiative will be a flexible and dynamic database structure that is being designed to accept data from a wide variety of sources. Individuals within the database will be characterized into relevant COPD subtypes as far as possible. Databases such as COPDGene ® are being used to define characteristics of clinically relevant subtypes. This initiative will provide a critical recourse to speed recruitment for clinical studies, reduce cost and facilitate identification of individuals that meet the study eligibility criteria.
The COPD Foundation recognizes the growing importance of an online presence and online social communication. In 2014, the COPD Foundation will continue to conduct patient and health care provider surveys, facilitate registration in research registries and clinical trials, and follow-up with patients to strengthen patient adherence and compliance with treatment. Surveys will identify constituent needs, while follow-up and feedback calls will provide the Foundation with invaluable insights into various gaps in COPD care and health management.
The COPD Foundation will expand on the success of the Information Line and plans to staff a new outboundcalling clinicians' component of the Information Line. Staffed by medical professionals, this expansion of the Information Line platform will provide a new resource to medical professionals. The Foundation will target calls to constituents to remind them and their family members to get critical immunizations such as those for seasonal influenza, pneumococcal, shingles, and pertussis. The COPD Foundation will partner with immunization clinics, retail drug stores and industry partners to enhance the success of this initiative. Plans for the expansion also include testing the success of an outbound calling program to reduce hospital readmissions of COPD patients. In addition, C.O.P.D. Information Line Associates will be utilized in the recently funded PCORI grant, Comparative Effectiveness of Peer-led Supplemental O2 Infoline for Patients and Caregivers and the Info Line will play a critical role in recruitment for the PPRN grant.
Conclusion
The COPD Foundation has accomplished a tremendous amount in the first 10 years of its existence, but there is so much more that needs to be done. While awareness of COPD has increased, there are still numerous challenges to face. COPD is now the third leading cause of death 39 and the second leading cause of disability in this country. 40 In 2009, two years after the launch of the Learn More Breathe Better® campaign, the largest COPD awareness campaign up until that time, the NIH reported that 68% of adults were aware of COPD, compared with 64% in 2008, and 49% in a 2004 survey. Among a high risk group, those who are currently smoking, awareness rose to 74% compared to 69% in 2008. 41 Even with the continued efforts and success of large scale awareness campaigns like Learn More, Breathe Better® and DRIVE4COPD, we must increase efforts to find more of the 12 million suspected of having COPD but still not diagnosed.
